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Abstract
Background: The impact of such recommendations after their implementation of guidelines has not usually been
evaluated. Herein, we assessed the impact and compliance with the Spanish Oncology Genitourinary Group
(SOGUG) Guidelines for toxicity management of targeted therapies in metastatic renal cell carcinoma (mRCC) in
daily clinical practice.
Methods: Data on 407 mRCC patients who initiated first-line targeted therapy during the year before and the year
after publication and implementation of the SOGUG guideline program were available from 34 Spanish Hospitals.
Adherence to SOGUG Guidelines was assessed in every cycle.
Results: Adverse event (AE) management was consistent with the Guidelines as a whole for 28.7 % out of 966
post-implementation cycles compared with 23.1 % out of 892 pre-implementation cycles (p = 0.006). Analysis of
adherence by AE in non-compliant cycles showed significant changes in appropriate management of hypertension
(33 % pre-implementation vs. 44.5 % post-implementation cycles; p < 0.0001), diarrhea (74.0 % vs. 80.5 %; p = 0.011)
and dyslipemia (25.0 % vs. 44.6 %; p < 0.001).
Conclusions: Slight but significant improvements in AE management were detected following the implementation
of SOGUG recommendations. However, room for improvement in the management of AEs due to targeted agents
still remains and could be the focus for further programs in this direction.
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Background
Targeted therapies have led to clinically meaningful ad-
vances in the treatment of patients with metastatic renal
cell carcinoma (mRCC).
Different antiangiogenic agents targeting different vari-
ous steps along the angiogenesis pathway, inhibiting
tumor growth and new vessel growth are available. Beva-
cizumab is a monoclonal antibody against VEGF-A [1].
Pazopanib is a highly potent tyrosine kinase inhibitor
(TKI) that targets vascular endothelial growth factor re-
ceptors (VEGFR) − 1, −2 and −3, platelet-derived growth
factor receptor (PDGFR) − α and β and c-Kit [2]. Sorafe-
nib is a multi-targeted kinase inhibitor that targets RAF
kinases (CRAF, BRAF, V600 BRAF) and tyrosine kinases
receptor (the stem cell factor c-KIT, fetal liver tyrosine
kinase 3 (FLT-3), VEGFR-2, VEGFR-3, and PDGFR-β)
[3]. Sunitinib inhibits PDGFR-α, PDGFR-β, VEGFR-1,
VEGFR-2, VEGFR-3, cKIT, FLT3, Colony-stimulating
factor 1 receptor (CSF-1R) and the Glial cell line-derived
neurotrophic factor receptor [4–6]. Finally, both approved
mammalian targets of rapamycin (mTOR inhibitors),
temsirolimus and everolimus, are derivatives of the natural
compound rapamycin. To inhibit mTOR signaling,
temsirolimus and everolimus interact with the cyto-
solic FK506-binding protein- 12 (FKBP12) to form a
complex which binds the mTOR. Through their
effects on mTOR, these drugs can inhibit cell proliferation
and induce apoptosis, in addition to the inhibiton of
angiogenesis [7, 8].
These novel antiangiogenic agents have different
mechanisms of action and exhibit a distinct toxicity pro-
file that requires appropriate monitoring and manage-
ment. Commonly reported toxicities for antiangiogenic
agents include hypertension, skin reactions, asthenia,
fatigue, gastrointestinal disturbances, hepatotoxicity,
metabolic dysfunctions and pneumonitis [9, 10]. Adverse
Event (AE) management is a critical component of the
overall care of patients with mRCC [11]. Subanalyses of
clinical trials in mRCC have concluded that some AEs
induced by these therapies may be associated with a
better outcome [12–14]. Thus, appropriate management
of adverse effects seems to be key in order to maintain
optimal doses in those patients who could obtain a
major benefit from treatment.
The use of valid guidelines can improve clinical prac-
tice, especially if accompanied by effective dissemination
strategies. However, both the context within which
guidelines are delivered and the nature of targeted
clinical behaviors may also influence their uptake. With
the aim of improving the AE management of targeted
therapies, the Spanish Oncology Genitourinary Group
(SOGUG) published in 2011[15] a Guide of recom-
mendations for AE management and launched a pro-
gram for the diffusion and implementation of this
guide. In this study we have evaluated the impact
and compliance with this Guide in the daily clinical
practice.
Methods
The Guidelines for the management of side effects of
targeted therapies were designed by the “Toxicity, Rare
Tumors and Hereditary Cancer Working Group” of the
SOGUG. They were published in March 2011 and
distributed in PDF and paper format among all
SOGUG members (245 Medical oncologists from 118
institutions). Additionally, free copies were available
for attendees at several national meetings on genito-
urinary tumors and became publically available through
a web application (http://www.sogug.es/Assets/docs/
manejo_farmacos_antidiana_cancer_renal.pdf ).
For the implementation of the Guidelines 12 oncolo-
gists from the above mentioned working group were
specifically trained on the recommendations provided by
the guides. Nine meetings all around the country were
held where clinical cases were presented by local oncolo-
gists and discussed with one of the trained oncologists.
In total, 120 oncologists became involved in the educa-
tional program.
Medical records were reviewed of adult patients
with histologically confirmed mRCC, who initiated
any targeted therapy (sunitinib, sorafenib, pazopanib,
everolimus, temsirolimus or bevacizumab) during the
year before (between March 2010 and February 2011;
pre-guidelines population) or the year after (between
January 2012 and December 2012; post-guideline
population) of publication, diffusion and implementa-
tion of the SOGUG Guideline program (Fig. 1).
Demographic, clinical and treatment data including
tests performed as screening or monitoring of AEs
were collected.
The main AEs related to the different treatment op-
tions were registered (Table 1) Hospital category was de-
fined by number of cases diagnosed with renal cancer
per year (c/y): primary hospital (≥ 20 c/y); secondary
hospital (11–19) c/y and tertiary hospital (0 to 10 c/y)
was also recorded.
Patients provided their written informed consent to
collect their data. This study was approved by the Spanish
Medicines Agency and by the Ethics and Clinical Research
Committee of Hospital of Navarra.
Non-compliance criteria with SOGUG Guidelines
were defined as: Hypertension: Blood pressure level was
not determined prior to start of treatment and in every
cycle. Perform dose reduction, dose interruption or
treatment discontinuation when the blood pressure
value was lower than 200/110 mmHg. Cardiac toxicity:
Basal and three-monthly assessments of left ventricular
ejection fraction (LVEF) were not performed. Perform
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dose reduction or dose interruption due to toxicity grade
1 or treatment discontinuation due to toxicity < 4.
Dermatologic toxicity: Information about suffering from
rash or hand-foot syndrome was not gathered from the
first cycle. Perform dose reduction or dose interruption
with toxicity of grade < 2. Hypothyroidism: Thyroid-
stimulating hormone (TSH) level was not determined
prior to treatment start and every three months. Carry
out dose interruption or treatment discontinuation due
to TSH levels. Hyperglycemia: Glucose level assessment
in every cycle was not performed. Dyslipemia: Choles-
terol, low density lipoprotein (LDL) and triglyceride
levels were not measured from the first cycle. Diarrhea:
Information about the development of diarrhea was not
gathered in all cycles. Carry out dose reduction or dose
interruption due to diarrhea grade <3. Pneumonitis:
Basal chest X-rays, pulmonary function and diffusing
capacity of the lungs for carbon monoxide (DLCO) as-
sessments were not performed. Clinical symptoms were
not recorded from the first cycle. Patients with positive
clinical symptoms were not subjected to chest X-rays
and peak expiratory flow (PEF) assessment. Carry out
dose reduction due to pneumonitis grade < 3, dose
interruption due to pneumonitis grade < 2 or treatment
discontinuation due to pneumonitis grade < 4. Hepatic
toxicity: Liver function tests were not performed prior to
start of treatment and at every cycle. Patients with ALT
increase between 3 and 8 times the upper limits of nor-
mal (ULN) and bilirubin normal value were not sub-
jected to weekly blood test. Carry out dose reduction or
dose interruption with ALT < 8 times ULNs value or
treatment discontinuation with ALT < 3 times ULN
value and bilirubin <2 times ULN value. Proteinuria:
Clinical information on proteinuria from the first cycle
of treatment was not recorded. Carry out dose reduction
or dose interruption due to proteinuria grade < 2 or
treatment discontinuation due to proteinuria grade <3.
Statistical analysis
The primary objective was to assess the SOGUG
Guidelines compliance before and after their publica-
tion and implementation. Secondary objectives in-
cluded treatment modifications due to Guideline
compliance and adherence to the SOGUG recommen-
dations according to the hospital category.
Fig. 1 Patient distribution: Patients were recruited during the year before (between March 2010 and February 2011; pre-guidelines population) or
the year after (between January 2012 and December 2012; post-guideline population) the publication, diffusion and implementation of the
SOGUG Guideline program
Table 1 Management of adverse events assessed according to targeted treatment___________________________________________________________________________________________________________
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Adherence to SOGUG Guidelines was assessed in
every cycle by evaluation of management of the pre-
specified AEs according to SOGUG Guideline recom-
mendations [15] (Table 1). AEs were recorded and rated
by an external data monitor according to National Can-
cer Institute Common Terminology Criteria for adverse
events (NCI CTCAE) version 4.0.
Student’s t-test or Mann-Withney U test were used
to compare quantitative variables and Pearson’s chi-
square test or Fisher’s exact test for qualitative vari-
ables. Tests were two-tailed with a significance level
of 5 %. Data were analysed using SPSS statistical
software v17.0.
Results
Thirty-four of the 40 institutions of SOGUG finally par-
ticipated in this retrospective, cross-sectional, multicen-
tre study. The analysis was conducted on 407 out of 410
mRCC patients (201 (49.4 %) pre-implementation, 206
(50.6 %) post-implementation). 1858 of 2103 treatment
cycles were deemed as evaluable (892 (48.0 %) pre-
implementation, 966 (52.0 %) post-implementation).
Most of the non-evaluable cycles were excluded
because they had not been administered within the
pre-specified timeframe. Table 2 shows patient cha-
racteristics. Proportion of men/women and ECOG
performance status were similar between pre- and
post-implementation groups (p > 0.05). Statistically sig-
nificant differences were observed regarding the age
of patients (median age: 60.5 years, 95 % IC: 58.4 to
61.8 vs. 64.5 years, 95 % IC 62.1 to 65.3; p = 0.003) in
the pre-implementation and post-implementation groups
respectively.
Cycle distribution and adherence to SOGUG Guide-
lines according to type of treatment are summarized
in Table 3. Overall, compliance with the SOGUG
Guidelines was significantly greater in the post-
implementation cycles compared with those of the
pre-implementation period (28.7 vs. 23.1 %; p = 0.006).
A meaningful increase of adherence to the Guideline
after the training program was observed with everoli-
mus treatment (32.3 % vs. 46.2 % p = 0.019), while
this did not occur with sunitinib or with temsirolimus
treatments, where only a numerical but not a signifi-
cant improvement was observed. Sorafenib showed a
significant decrease in compliance with the guidelines
(10.8 % vs. 2.2 %; p = 0.013). Pazopanib comparative
analysis was not carried out due to the low number
of patients included in the pre-implementation group.
SOGUG recommendations were not fulfilled as a
whole in 71 % of cycles (Table 3). However, when the
management of each type of AE in those cycles was
analyzed, an improvement was observed in the manage-
ment of some AEs. Overall, significant increase in the
appropriate management of hypertension (pre-imple-
mentation 33 % vs. 44.5 % post-implementation; p <
0.0001), diarrhea (74.0 % vs. 80.5 %; p = 0.011) and dysli-
pemia (25.0 % vs. 44.6 %; p < 0.001) was observed in
those cycles where SOGUG recommendations were not
fulfilled as a whole (Table 3). In addition, two agents
showed significant increase in guideline compliance
in some AEs: sunitinib in the management of hyper-
tension (43.5 % vs. 53.4; p = 0.008) and diarrhea (68.8
vs. 82.5; p < 0.0001) and everolimus in the manage-
ment of dyslipemia (25.0 % vs. 53.8 %; p < 0.0001;
Table 3).
The most frequent reason for non-compliance with
the Guidelines was the lack of test performing (Table 4):
basal and follow-up assessments of blood pressure,
LVEF, TSH glucose, chest X-rays, pulmonary function,
DLCO and liver function were not performed as
frequently as recommended by the Guidelines. Inappro-
priate dose reductions, interruptions or treatment
discontinuation were not reasons for non-compliance
with Guidelines in the vast majority of non-compliant
cycles (Table 4).
Table 2 Patients characteristics




Mean age (SD), years 61.9 (12.0)





Histology, n (%) 399





Collecting Duct 1 (0.3)
Others 4 (1.0)







* Some patients received more than one treatment
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Pre 534 Post 443 Pre 157 Post 90 Pre 1 Post 209 Pre 130 Post 145 Pre 56 Post 69 Pre 14 Post 10 Pre 892 Post 966
Overall compliance, n cycles (%)
Yes 136 (25.5) 123 (27.8) 17 (10.8) 2 (2.2)* 0 (0.0) 68 (32.5) 42 (32.3) 67 (46.2)* 8 (14.3) 17 (24.6) 3 (21.4) 0 (0.0) 206 (23.1) 277 (28.7)*
No 398 (75.5) 320 (72.2) 140 (89.2) 88 (97.8) 1 (100) 141 (67.5) 88 (67.7) 78 (53.8) 48 (85.7) 52 (75.4) 11 (78.6) 10 (100) 686 (76.9) 689 (71.3)
Guidelines compliance by adverse event, n cycles (%)a
Hypertension 173 (43.5) 171 (53.4)* 1 (0.7) 0 (0.0) 0 (0.0) 69 (48.9) – – – – 9 (81.8) 9 (90.0) 183 (33.3) 249 (44.5)£
Cardiac toxicity 113 (28.4) 87 (27.2) – – – – – – – – – – 113 (28.4) 87 (27.2)
Skin toxicity 398 (100) 320 (100) 140 (100) 88 (100) – – – – 48 (100) 52 (100)- – – 586 (100) 460 (100)
Hypothyroidism 172 (43.2) 157 (49.1) – – – – – – – – – – 172 (43.2) 157 (49.1)
Diarrhea 274 (68.8) 264 (82.5)£ 124 (88.6) 73 (83.0) 1 (100) 105 (74.5) – – – – – – 399 (74.0) 442 (80.5)*
Hyperglycemia – – – – – – 63 (71.6) 53 (67.9) 28 (58.3) 39 (75.0) – – 91 (66.9) 92 (70.8)
Dyslipemia – – – – – – 22 (25.0) 42 (53.8) £ 12 (25.0) 16 (30.8) – – 34 (25.0) 58 (44.6)#
Pneumonitis – – – – – – 53 (60.2) 42 (53.8) 31 (64.6) 32 (61.5) – – 84 (61.8) 74 (56.9)
Liver toxicity – – – – 1 (100) 37 (26.2) – – – – – – 1 (100) 37 (26.2)
Proteinuria – – – – – – – – – – 2 (18.2) 0 (0.0) 2 (18.2) 0 (0.0)
a (%): percentage of compliance in relation to the total cycles in which the SOGUG guidelines were not-complied with











Overall, patients from pre- and post-implementation
groups received a median (Q1–Q3) of 4.0 (2.0–6.0) and
4.0 (3.0–6.0) cycles, respectively. Table 5 shows the
number of cycles administered according to the targeted
agent. In all, 48 (11.8 %) patients needed dose reduc-
tions, 33 (8.1 %) dose interruptions, 24 (5.9 %) treatment
discontinuation and 4 (1.0 %) dose increases. No statisti-
cally significant differences were observed between pre
and post-implementation groups for any treatment
action taken or targeted agent (Table 5). With regard
to the total 1858 cycles, in 58 (3.1 %) of them a dose
reduction was carried out, in 38 (2.0 %) a dose













Hypertension, n cycles (%) 374 227 73 – – 3
Basal BP not recorded – 226 (99.6) 27 (37.0) – – 3 (100)
BP not recorded 363 (97.1) 137 (60.4) 45 (61.6) – – –
Dose reduction 9 (2.4) – 1 (1.4) – – –
Dose interruption 1 (0.3) – – – – –
Treatment discontinuation 2 (0.5) 1 (0.4) – – – –
Cardiac toxicity, n cycles (%) 518 – – – – –
Non-recorded basal LVEF 145 (28.0) – – – – –
LVEF not performed 484 (93.4) – – – – –
Dose reduction 1 (0.2) – – – – –
Dose interruption 1 (0.2) – – – – –
Treatment discontinuation 2 (0.4) – – – – –
Hypotyroidism, n cycles (%) 389 – – – – –
Basal TSH not recorded 114 (29.3) – – – – –
TSH > 10 mU/l not-performed 358 (92.0) – – – – –
Dose interruption 2 (0.5) – – – – –
Diarrhea, n cycles (%) 180 31 36 – – –
Not recorded 165 (91.7) 29 (93.5) 36 (100) – – –
Dose reduction 12 (6.7) 1 (3.2) – – – –
Dose interruption 3 (1.7) 1 (3.2) – – – –
Hyperglycemia, n cycles (%) – – – 50 33 –
Not recorded – – – 25 (100) 33 (100) –
Dyslipemia, n cycles (%) – – – 102 72 –
Not recorded – – – 102 (100) 72 (100) –
Pneumonitis, n cycles (%) – – – 71 37 –
Basal data not recorded – – – 66 (93.0) 35 (94.6) –
Follow-up data not recorded – – – 5 (7.0) 1 (2.7) –
Treatment discontinuation – – – 2 (2.8) 1 (2.7) –
Liver toxicity, n cycles (%) – – 104 – – –
Basal liver function not recorded – – 19 (18.3) – – –
Liver function not recorded – – 81 (77.9) – – –
ALT increase > 3–8 ULN – – 5 (4.8) – – –
Dose interruption – – 2 (1.9) – – –
Treatment discontinuation – – 1 (1.0) – – –
Proteinuria, n cycles (%)
Not performed – – – – – 19 (100)
Length of cycles according to routine clinical practice: sunitinib 6 weeks; other treatments 4 weeks
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Pre 143 Post 108 Pre 43 Post 19 Pre 1 Post 55 Pre 34 Post 36 Pre 19 Post 18 Pre 4 Post 1
Number of cycles administered
Median (Q1–Q3) 4.0 (2.0–5.0) 4.0 (2.0–5.0) 3.0 (2.0–5.0) 3.0 (2.0–8.0) 1.0 (1.0–1.0) 3.0 (2.0–5.0) 3.0 (2.0–5.0) 4.0 (2.0–6.0) 2.0 (1.0–4.0) 2.5 (2.0–4.0) 3.5 (2.5–4.5) 10.0 (10.0–10.0)
*Treatment modification, n cycles (%)
Dose reduction 24 (16.8) 16 (14.8) 4 (9.3) 1 (5.3) 0 (0.0) 4 (7.3) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Dose interruption 8 (5.6) 9 (8.3) 2 (4.7) 2 (10.5) 0 (0.0) 4 (7.3) 3 (8.8) 4 (11.1) 1 (5.3) 1 (5.6) 0 (0.0) 0 (0.0)
Treatment discontinuation 6 (4.2) 5 (4.6) 3 (7.0) 0 (0.0) 0 (0.0) 5 (9.1) 0 (0.0) 3 (8.3) 2 (10.5) 2 (11.1) 0 (0.0) 0 (0.0)
Dose increased 0 (0.0) 0 (0.0) 1 (2.3) 2 (10.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)











interruption, in 26 (1.4 %) a treatment discontinu-
ation and in 4 (0.2 %) an increase of dose. No signifi-
cant differences after the implementation program
were observed for any treatment either.
Regarding the hospital category, a significantly greater
adherence to the SOGUG recommendations was ob-
served after the program was launched in those hospitals
with a higher number of cases of renal cancer per year
(18.2 vs. 30.7; p < 0001; Fig. 2). Hypertension (30 % vs.
56.0 % p < 0001) and hyperglycemia (60.5 % vs. 90.9 %;
p < 0.001) were the adverse events that showed a signifi-
cantly higher compliance with the guide after the
implementation program in primary hospitals, and
diarrhea (91.2 % vs. 96.5 %; p = 0.033) in secondary
hospitals.
Discussion
This study assessed the impact of the implementation
and diffusion program of SOGUG guideline[15] for the
management of targeted therapies in daily clinical
practice.
Proper management of adverse effects ensures that
patients receive optimal benefit from these newer
therapies[9]. The aim of these Guidelines was to pro-
vide oncologists with a useful, easily handled tool in
relation to strategies for prevention and management
of AEs due to targeted agents. Overall, the present
analysis showed a slight but significant improvement
of adverse event management as a whole after the
implementation of the SOGUG recommendations,
and in particular with regard to hypertension,
diarrhea and dyslipemia. Primary hospitals showed
a meaningful increase in adherence to SOGUG
Guidelines.
These recommendations reflect the consensus from
an expert working group of medical oncologists.
Nevertheless, clinical judgment based on the medical
history and clinical status of the individual patient is
actually what determines the appropriate manage-
ment and the actions to be taken in response to side
effects of targeted treatments. Strategies to evaluate
the effectiveness and efficiency of guidelines dissem-
ination and implementation have been also reported
by different authors [16, 17]. Although the use of
guidelines can improve clinical practice [18], both
the context within which guidelines are delivered and
the nature of target clinical behaviors may also influ-
ence their uptake [16]. In addition, clinical practice
has proved remarkably resilient to recommendations
for practice change embedded in clinical practice
guidelines [19].
Although SOGUG recommendations were not com-
plied with as a whole in nearly three-quarters of man-
aged cycles, when adherence was analyzed by type of
AE, appropriate management of some toxicities in-
creased meaningfully. In particular, improvements were
observed in hypertension and diarrhea management in
sunitinib cycles and dyslipemia management with evero-
limus. Diarrhea is one of the most common toxicities,
observed both with TKIs (50–60 %) and mTOR inhibi-
tors (30 %) [10, 11]. Hypertension is, by itself, associated
with organ damage, including left ventricular hyper-
trophy, congestive heart failure, coronary artery disease
or myocardial infarction, and it is also one of the prime
causes of proteinuria [20]. Optimal management of
hypertension hypothetically reduces the appearance of
long-term cardiovascular diseases. Hypertension occurs
in 17–45 % of TKI-treated patients (40 % pazopanib,
30 % sunitinib, 4–11 % sorafenib) and bevacizumab
(3–11 %) patients[10], but is rarely described with
mTOR inhibitors[11]. Hypertension, in particular of
grade 3, has been associated with a greater treatment
response [21, 22] and may be considered an efficacy
biomarker in patients treated with VEGF inhibitors
[13, 20]. It presents early, within 3 to 4 weeks of treat-
ment initiation [9, 23]. Hypertension should not be a
reason for dose reduction nor treatment interruption
as it can be safely managed with adequate treatment.
Metabolic changes as hyperglycemia (26–57 %) or dys-
lipemia (52–77 %) are associated mainly with mTOR
inhibitors [11].
SOGUG Guideline recommended performing at base-
line and during therapy several tests that permit preven-
tion and early detection of adverse events such as fatal
hepatic failure, pneumonitis, hypertension or hypergly-
cemia, among others. Similar recommendations have
been published by several authors [9–11, 20]. In this
study, the most frequent reason for non-compliance
Fig. 2 Adherence to SOGUG Guidelines according to hospital
category defined as number of cases diagnosed with renal cancer
per year (c/y): 1st category hospital (≥ 20 c/y); 2nd category hospital
(11–19) c/y and 3rd category hospital (0 to 10 c/y)
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with the Guidelines was failure to perform tests. The
majority of laboratory abnormalities do not require
intervention in most cases [11]. It is often difficult to
differentiate between treatment-induced and disease-
induced changes in some metabolic or laboratory
parameters [11]. On the other hand, at RCC onset,
elderly patients often suffer from some chronic
diseases such as hypertension or dyslipemia, which
requires treatment and monitoring to be conducted in
the primary care setting. Based on these consider-
ations, such tests were probably performed though not
recorded in the medical history because their out-
comes either did not have any notable significance or
were performed by primary care physicians. Even so,
one of the aims pursued with the implementation of the
Guidelines was to make oncologists aware of the import-
ance of conducting such tests and their monitoring.
The maximum benefit from antiangiogenic drugs is
obtained in patients who can stay on therapy continu-
ously over a prolonged period of time. Continuous
therapy is possible only if the associated adverse events
are effectively managed [20]. After SOGUG Guidelines
implementation, we expected a significant decrease in
dose reduction and temporary or final interruptions of
treatment, but this was not observed. Treatment modifi-
cations rates were lower than those observed in other
observational studies performed in the real-world clin-
ical setting [24, 25]. The percentages of dose reductions/
dose interruptions in the present study are lower
than those reported from sunitinib’s pivotal [26] and
SWITCH [27] trials. But in the range of that was shown
in the EFFECT [28] study where 11 % of the patients
treated with treatment schedule 4 weeks of treatment/
2 weeks off, needed treatment interruption due to
adverse events. It is possible that in our study the use of
non-standard treatment schedules, not permitted in
clinical trials, may have contributed to maintain
the doses without the need for dose reductions or in-
terruptions during treatment. In addition, this is a
cross-sectional study in which the treatment is ana-
lyzed in one period of time compared with to another
period of time, therefore the data collected about pa-
tient’s exposure to the drug is less than in a clinical
trial.
Methodological limitations need to be taken into con-
sideration in this study. Firstly this study evaluated the
Spanish Guidelines which limits the applicability in
other countries. In addition, the outcomes may not re-
flect the complexity of the Guidelines. Non-compliance
criteria were simplified for the purpose of making data
collection feasible. Only the management of the most
representative AEs for every treatment was recorded,
which suggests the possibility of measurement bias.
Secondly, the lack of patients before implementation
Guidelines in the pazopanib treatment group and the
small sample size of the bevacizumab group did not
allow changes in outcomes to be detected in 61 of the
407 patients included.
Conclusion
Slight but significant improvements in adverse event
management in compliance with SOGUG recommenda-
tions were detected following their dissemination and
implementation; in particular in hypertension, diarrhea
and dyslipemia. Educational programs focused on the
implementation of clinical guidelines can impact on the
management of adverse events. However, room for im-
provement in the management of adverse events due to
targeted agents still remains and this could be the
focus for further programs in this direction. SOGUG
Guidelines are already being updated to make them
more accurate and precise in order to be really useful
for management of AEs.
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